Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lorcaserin

EISAI

Eisai launches thyroid cancer therapy Lenvima in UK

The UK is its first European market, with wider EU roll out expected in coming months

- PMLiVE

Takeda files block on generic diet pill launch

Contrave is succumbing to patent attacks just months after being approved

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

EISAI

Eisai to share clinical trial data via external website

Company aims to further promote transparency in the industry

- PMLiVE

Kythera bags FDA approval for double chin therapy

Comes as cosmetics industry sees major growth

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

EISAI

Eisai to make 200 cuts to US operations

Japanese firm says the restructure will help it stay competitive

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

- PMLiVE

Novo Nordisk sheds autoimmune portfolio to BMS

Continues the trend of pharma buying up unwanted assets from rival firms

UK flag

Cancer Drugs Fund a ‘missed opportunity’, says MP

Chair of the Liberal Democrat health committee Paul Burstow says the CDF should have gone further

- PMLiVE

Positive data in Saxenda diabetes prevention study

Drug found to improve blood glucose and blood pressure levels

- PMLiVE

Merck and Eisai link up on anti-PD-1 combinations

Will test Keytruda with both Lenvima and Halaven 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links